We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Medpace (MEDP) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest close session, Medpace (MEDP - Free Report) was down 1.49% at $530.19. The stock trailed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the provider of outsourced clinical development services have appreciated by 15.17% over the course of the past month, outperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on July 22, 2026. The company's upcoming EPS is projected at $4.08, signifying a 31.61% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $699.51 million, up 15.95% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 31.59. For comparison, its industry has an average Forward P/E of 15.5, which means Medpace is trading at a premium to the group.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. MEDP's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Why Medpace (MEDP) Dipped More Than Broader Market Today
In the latest close session, Medpace (MEDP - Free Report) was down 1.49% at $530.19. The stock trailed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the provider of outsourced clinical development services have appreciated by 15.17% over the course of the past month, outperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on July 22, 2026. The company's upcoming EPS is projected at $4.08, signifying a 31.61% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $699.51 million, up 15.95% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 31.59. For comparison, its industry has an average Forward P/E of 15.5, which means Medpace is trading at a premium to the group.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. MEDP's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.